state food and drug administration
Shanghai MengKe Pharma To Develop MRX-I Antibiotic For Chinese Market
MicuRx Pharma and Shanghai Zhangjiang Biomedical Industry Venture Capital today announced a joint venture to develop MRX-I for the Chinese market.
Ironwood, AstraZeneca To Develop Linaclotide In China
AstraZeneca and Ironwood Pharmaceuticals, Inc. announced this week an agreement to co‐develop and co‐commercialize Ironwood’s linaclotide in China.
China Plans To Launch Hepatitis E Vaccine ‘This Year’
After more than a year of scrutiny and inspection, a hepatitis E vaccine developed by Chinese scientists should be available by the end of the year.
China Biologic Receives SFDA Approval To Begin Human Fibrinogen Trials
China Biologic Products, Inc. has received SFDA approval to begin clinical trials for human fibrinogen as a treatment for congenital fibrinogen deficiency and acquired fibrinogen deficiency.
China Approves First Microarray Platform For In Vitro Diagnostic Use
China's State Food and Drug Administration has given clearance to Affymetrix's GeneChip® System 3000Dx v.2 for in vitro clinical diagnostic use.
Tasly Pharma To Conduct Phase III Angina Pectoris Trials For Its Dantonic Pill
Tasly Pharma is conducting two global Phase III trials for T89, also known as the Dantonic® pill, that the company hopes will become the first traditional Chinese medicine to receive FDA approval in the United States.
AstraZeneca Invests US$200m Into Manufacturing Facility In China Medical City
AstraZeneca today announced a US$200 million investment in a new manufacturing facility, located in China Medical City, Taizhou, Jiangsu province in Eastern China.
Simcere Receives CFDA Approval For Anti-Rheumatic Drug Iremod
The State Food and Drug Administration has approved Simcere Pharmaceutical Group's new anti-rheumatic drug, Iremod, used to treat symptoms of active rheumatic arthritis.
